Story · Medicine & Biotech

Windward prices $175M IPO to advance China-licensed lung drugs

1 outlet · first reported by BioPharma Dive 2h ago

Coverage, in order

  1. 2h ago
    BioPharma Dive indie
    Windward prices $175M IPO to advance China-licensed lung drugs

    The Swiss biotech has two prospects it sees as having the potential to outcompete AstraZeneca and Amgen's blockbuster asthma treatment Tezspire.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.